SYRS News and Press, Syros Pharmaceuticals Inc. From 08/05/20

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as fo...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 6, 2020 to report its second quarter 2020 financial results and provide ...

CAMBRIDGE, Mass. , July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes ther...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a change to its presentation time at the upcoming JMP Securities Hematology and Oncology Forum. Updated details are as follows: JMP Securities Hematology an...

The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows: ...

The company in bars is, I have noticed, either very good or very bad; there seems to be some force of a minor destiny that draws good company to the same place at the same time ." - John Glassco, Memoirs of Montparnasse Today, we revisit a Tier 4 biotech concern that continues to adva...

Highly Selective and Potent Oral CDK7 Inhibitor Shows Robust Anti-Tumor Activity in Colorectal Cancer Models Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly...

CAMBRIDGE, Mass. , May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Par...

Investing in companies with superior growth rates can produce outstanding returns over the long term. A stock is essentially a share in the ownership of a business, and the price of the stock will follow the value of the business over time. When the business is growing rapidly and ideally ac...